Probiodrug

  • Probiodrug floated on Euronext Amsterdam with an initial market capitalisation of €102m
  • Proceeds of the offering will be used to execute the phase 2a study of its lead product in Alzheimer’s patients
  • Efforts resulted in an order book mainly made up of long-term specialist investors, despite turbulent markets